Sarepta Therapeutics (SRPT) Debt to Equity: 2011-2025
Historic Debt to Equity for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $0.81.
- Sarepta Therapeutics' Debt to Equity fell 19.29% to $0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.81, marking a year-over-year decrease of 19.29%. This contributed to the annual value of $0.74 for FY2024, which is 48.33% down from last year.
- As of Q3 2025, Sarepta Therapeutics' Debt to Equity stood at $0.81, which was down 3.34% from $0.84 recorded in Q2 2025.
- In the past 5 years, Sarepta Therapeutics' Debt to Equity ranged from a high of $4.01 in Q4 2022 and a low of $0.74 during Q4 2024.
- Over the past 3 years, Sarepta Therapeutics' median Debt to Equity value was $1.14 (recorded in 2024), while the average stood at $1.21.
- In the last 5 years, Sarepta Therapeutics' Debt to Equity skyrocketed by 239.41% in 2022 and then plummeted by 64.09% in 2023.
- Over the past 5 years, Sarepta Therapeutics' Debt to Equity (Quarterly) stood at $1.18 in 2021, then spiked by 239.41% to $4.01 in 2022, then tumbled by 64.09% to $1.44 in 2023, then crashed by 48.33% to $0.74 in 2024, then dropped by 19.29% to $0.81 in 2025.
- Its last three reported values are $0.81 in Q3 2025, $0.84 for Q2 2025, and $1.00 during Q1 2025.